X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Celebrating diversity in the biopharmaceutical industry

By Andrew Powaleny  |    June 30, 2016
At PhRMA, we often talk about the complexity of developing innovative medicines. Critical to researching new medicines is a workforce that combines sheer brainpower with a level of perseverance...   Read More

Burden on patients: Insurance benefit design’s impact on patient access to medicines

By Allyson Funk  |    June 30, 2016
Last week, we looked at access to medicines in health insurance exchanges for HIV/AIDS, oncology, cystic fibrosis, mental health and multiple sclerosis. The analysis by Avalere Health presents data...   Read More

Science of Hope: Incorporating the patient perspective

By Andrew Powaleny  |    June 29, 2016
For many of America’s biopharmaceutical researchers and scientists, seeing the positive effects of their work on the lives of patients is what encourages them to keep striving. Dr. Al Sandrock, chief...   Read More

Ask About Adherence: New resources from The Medication Adherence Alliance

By Samantha Dougherty  |    June 28, 2016
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we spotlight a new website from The Medication Adherence Alliance, an...   Read More

Medicare Monday: What is in the 2016 Medicare Trustees report

By Allyson Funk  |    June 27, 2016
Every year, the Trustees of the Social Security and Medicare trust funds release an annual report on the current and projected status of the two programs. The 2016 report on Medicare was released...   Read More

New PwC report finds medicine spending still small share of health spending, concerns may trigger ‘false alarms’

By Holly Campbell  |    June 23, 2016
In case you missed it, PwC Health Research Institute’s (HRI) Medical Cost Trend: Behind the Numbers 2017 report highlights medicine spending is “still a relatively small portion of overall health...   Read More

Burden on patients: Access to medicines in health insurance exchange plans

By Allyson Funk  |    June 23, 2016
Access to prescription medicines is critical to help patients manage their chronic conditions and maximize quality of life. Unfortunately, even with insurance coverage, many patients still struggle...   Read More

Ask About Adherence: Q&A with PhRMA Foundation Grant Awardee - Marisa Schauerhamer

By Samantha Dougherty  |    June 22, 2016
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Marisa Schauerhamer, a 2016 PhRMA Foundation Young Investigator Adherence grantee   Read More

Medicare Monday: What they are saying about MedPAC’s recommendations

By Allyson Funk  |    June 20, 2016
Back in April, we previewed MedPAC’s recommendations and expressed concern and opposition to the sweeping recommended changes to Part D that taken together could harm beneficiaries by eroding...   Read More

Science of Hope: Learning from setbacks

By Andrew Powaleny  |    June 20, 2016
America’s biopharmaceutical research companies are committed to developing new treatments and cures that improve health and save patient lives. Jen O’Neil, principal oncology scientist at Merck,...   Read More

Seizing the opportunity to rebuild U.S. leadership in STEM

By Anne McDonald Pritchett, PhD  |    June 17, 2016
The United States is not only falling behind other countries on many key science, technology, engineering and mathematics (STEM) indicators, but our public investment in STEM education has steadily...   Read More

Empowering consumers and improving access to out-of-pocket cost information

By Allyson Funk  |    June 16, 2016
A well-informed consumer is an engaged and empowered patient. One policy solution for delivering innovative treatments to patients is to engage and empower consumers by making more information about...   Read More

Forced pharmaceutical localization fails to deliver

By Guest Contributor  |    June 15, 2016
  Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

America’s biopharmaceutical researchers advance the science of hope in new “From Hope to Cures” ads

By Ieva M. Augstums  |    June 14, 2016
Jen and Yingzi are in the problem-solving business. Every day, they tackle one of the toughest health care problems: cancer. While many others like them across the biopharmaceutical industry work...   Read More

Medicare Monday: What a one-size-fits-all treatment means for arthritis patients and quality of life

By Nicole Longo  |    June 13, 2016
As we’ve learned in recent case studies, the specific course of treatment chosen for a patient managing a serious disease can have real implications for their quality of life. Patients and their...   Read More

Advancing the science of hope

By Andrew Powaleny  |    June 13, 2016
Developing new medicines is a challenging undertaking, and the science is only getting harder. As our understanding of science grows, so does the complexity of developing new medicines, particularly...   Read More

Why incorporating patients’ perspectives matters

By Andrew Powaleny  |    June 10, 2016
America’s biopharmaceutical research companies have long been dedicated to researching and developing new medicines that enable patients to live longer, healthier lives. Patients’ voices are becoming...   Read More

Canada’s innovation challenge

By Mark Grayson  |    June 9, 2016
Canada is well-respected as a global leader. While no country is free of problems, Canada enjoys a strong economy, largely happy and healthy citizens and strong alliances with nations throughout the...   Read More

Medicare Monday: What actually happened with Medicare Part D

By Nicole Longo  |    June 6, 2016
Earlier this year, we looked at what people said would happen with the passage and implementation of Medicare Part D and what has actually happened in the first 10 years of the program.   Read More

New report: Decade of breakthroughs in cancer

By Emma Van Hook  |    June 2, 2016
The pace of science is yielding remarkable innovation for cancer patients as we learn more about the underlying factors driving the spread and growth of cancer. These advances are opening new doors...   Read More

New Report: Part B proposal is more aggressive than previous efforts

By Kelsey Lang  |    June 1, 2016
In the more than 1,300 comments submitted to the Centers for Medicare & Medicaid Services (CMS) on the Part B Drug Payment Model, a wide range of organizations raised concern with the unprecedented...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."